- Home
- ALLK vs NXGL Comparison
ALLK vs NXGL Comparison
Compare ALLK & NXGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLK
- NXGL
- Stock Information
- Founded
- ALLK 2012
- NXGL 1997
- Country
- ALLK United States
- NXGL United States
- Employees
- ALLK N/A
- NXGL N/A
- Industry
- ALLK Biotechnology: Pharmaceutical Preparations
- NXGL Medical/Dental Instruments
- Sector
- ALLK Health Care
- NXGL Health Care
- Exchange
- ALLK Nasdaq
- NXGL Nasdaq
- Market Cap
- ALLK 23.0M
- NXGL 18.9M
- IPO Year
- ALLK 2018
- NXGL 2021
- Fundamental
- Price
- ALLK $0.33
- NXGL $2.70
- Analyst Decision
- ALLK Hold
- NXGL
- Analyst Count
- ALLK 3
- NXGL 0
- Target Price
- ALLK $2.00
- NXGL N/A
- AVG Volume (30 Days)
- ALLK 2.2M
- NXGL 36.7K
- Earning Date
- ALLK 05-08-2025
- NXGL 05-12-2025
- Dividend Yield
- ALLK N/A
- NXGL N/A
- EPS Growth
- ALLK N/A
- NXGL N/A
- EPS
- ALLK N/A
- NXGL N/A
- Revenue
- ALLK N/A
- NXGL $8,688,000.00
- Revenue This Year
- ALLK N/A
- NXGL $51.39
- Revenue Next Year
- ALLK N/A
- NXGL $36.14
- P/E Ratio
- ALLK N/A
- NXGL N/A
- Revenue Growth
- ALLK N/A
- NXGL 112.47
- 52 Week Low
- ALLK $0.22
- NXGL $1.84
- 52 Week High
- ALLK $1.56
- NXGL $5.10
- Technical
- Relative Strength Index (RSI)
- ALLK 60.40
- NXGL 46.52
- Support Level
- ALLK $0.31
- NXGL $2.54
- Resistance Level
- ALLK $0.33
- NXGL $2.99
- Average True Range (ATR)
- ALLK 0.00
- NXGL 0.26
- MACD
- ALLK 0.00
- NXGL 0.01
- Stochastic Oscillator
- ALLK 78.50
- NXGL 62.43
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.
About NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating, and cross-linking technologies.